Skip to the beginning of the images gallery

Erenumab (anti-CALCRL), for ELISA,Functional Assay,Flow cytometry,Kinetics (BLI),Kinetics (SPR) various applications, specific to CALCRL, >95%, high purity, Human IgG2SA, Antibody of CGRP receptor

Azide Free
Carrier Free
ExactAb™
Low Endotoxin
Recombinant
Validated
≥95%(SDS-PAGE&SEC)
Lot by Lot

Features and benefits

Short Overview:
Purity>95% (SDS-PAGE&SEC); Endotoxin Level<1.0EU/mg; Human IgG2Sa; CHO; ELISA, FACS, Functional assay, Animal Model; Unconjugated
Application: ELISA,Functional Assay,Flow cytometry,Kinetics (BLI),Kinetics (SPR)
Species reactivity(Reacts with): Cynomolgus monkey,Human
Isotype: Human IgG2SA

Application:

Animal Model
ELISA
Flow Cytometry
Functional Assay

Item Number

Ab170518

Grouped product items
SKU	Size	Availability	Price
Ab170518-100μg	100μg	Available within 8-12 weeks(?) Production requires sourcing of materials. We appreciate your patience and understanding.	$49.90
Ab170518-1mg	1mg	In stock	$237.90
Ab170518-5mg	5mg	In stock	$657.90
Ab170518-10mg	10mg	Available within 8-12 weeks(?) Production requires sourcing of materials. We appreciate your patience and understanding.	$1,047.90

Purity>95% (SDS-PAGE&SEC); Endotoxin Level<1.0EU/mg; Human IgG2Sa; CHO; ELISA, FACS, Functional assay, Animal Model; Unconjugated

View related series

Accession#:Q16602 CALCRL CGRP receptor Antibody Gene ID:10203

Basic Description

Product Name	Erenumab (anti-CALCRL), for ELISA,Functional Assay,Flow cytometry,Kinetics (BLI),Kinetics (SPR) various applications, specific to CALCRL, >95%, high purity, Human IgG2SA
Synonyms	Calcitonin gene related peptide type 1 receptor antibody; Calcitonin gene-related peptide type 1 receptor antibody; Calcitonin receptor like antibody; Calcitonin receptor like receptor antibody; Calcitonin receptor-like receptor antibody; Calcrl antibody;
Specifications & Purity	ExactAb™, Validated, Carrier Free, Low Endotoxin, Azide Free, Recombinant, ≥95%(SDS-PAGE&SEC), Lot by Lot
Specificity	CALCRL
Application	ELISA,Functional Assay,Flow cytometry,Kinetics (BLI),Kinetics (SPR)
Conjugation	Unconjugated
Grade	Azide Free, Carrier Free, ExactAb™, Low Endotoxin, Recombinant, Validated
Action Type	ANTAGONIST
Mechanism of action	Antibody of CGRP receptor
Product Description	Erenumab is a fully human monoclonal antibody. Erenumab inhibits the calcitonin gene–related peptide (CGRP) receptor. Erenumab can be used for the prevention of episodic migraine. Purity:>95% (SDS-PAGE&SEC) Endotoxin Level:< 1.0EU/mg

Product Properties

Antibody Type	Primary antibody
Clonality	Recombinant
Isotype	Human IgG2SA
Light Chain Type	lambda
SDS-PAGE	27.7 kDa (Light Chain) & 52.0 kDa (Heavy Chain), under reducing conditions; 175.2 kDa, under non-reducing conditions.
Purification Method	Protein A purified
Purity	>95%
Source	CHO supernatant
Form	Liquid
Concentration	Lot by Lot
Storage Temp	Store at -80°C,Avoid repeated freezing and thawing
Shipped In	Ice chest + Ice pads
Stability And Storage	Store at -80℃ for 24 months. Upon delivery aliquot. Avoid freeze/thaw cycle.
CAS	1582205-90-0

Images

Erenumab (anti-CALCRL) (Ab170518) - SEC
The purity of Erenumab (anti-CALCRL) (Ab170518) is more than 95% verified by HPLC.

Associated Targets

RAMP1 Tclin Receptor activity-modifying protein 1 0 Activities

Discover Target: RAMP1

Activity Type	Activity Value -log(M)	Mechanism of Action	Activity Reference	Publications (PubMed IDs)

CALCRL Tclin Calcitonin gene-related peptide type 1 receptor 0 Activities

Discover Target: CALCRL

Activity Type	Activity Value -log(M)	Mechanism of Action	Activity Reference	Publications (PubMed IDs)

Database links

IMGT/mAb-DB	618

Certificates

Certificate of Analysis(COA)

Enter Lot Number to search for COA:

To view the certificate results,please click on a Lot number.For Lot numbers from past orders,please use our order status section

2 results found

Lot Number	Certificate Type	Date	Item
ZJ24F0102480	Certificate of Analysis	Jan 18, 2024	Ab170518
ZJ24F0102479	Certificate of Analysis	Jan 18, 2024	Ab170518

References

1. Hansen JM, Hauge AW, Olesen J, Ashina M. (2010) Calcitonin gene-related peptide triggers migraine-like attacks in patients with migraine with aura.. Cephalalgia, 30 (10): (1179-86). [PMID:20855363]
2. Sun H, Dodick DW, Silberstein S, Goadsby PJ, Reuter U, Ashina M, Saper J, Cady R, Chon Y, Dietrich J et al.. (2016) Safety and efficacy of AMG 334 for prevention of episodic migraine: a randomised, double-blind, placebo-controlled, phase 2 trial.. Lancet Neurol, 15 (4): (382-90). [PMID:26879279]
3. Shi L, Lehto SG, Zhu DX, Sun H, Zhang J, Smith BP, Immke DC, Wild KD, Xu C. (2016) Pharmacologic Characterization of AMG 334, a Potent and Selective Human Monoclonal Antibody against the Calcitonin Gene-Related Peptide Receptor.. J Pharmacol Exp Ther, 356 (1): (223-31). [PMID:26559125]
4. Paemeleire K, MaassenVanDenBrink A. (2018) Calcitonin-gene-related peptide pathway mAbs and migraine prevention.. Curr Opin Neurol, 31 (3): (274-280). [PMID:29432219]
5. Dodick DW, Ashina M, Brandes JL, Kudrow D, Lanteri-Minet M, Osipova V, Palmer K, Picard H, Mikol DD, Lenz RA. (2018) ARISE: A Phase 3 randomized trial of erenumab for episodic migraine.. Cephalalgia, 38 (6): (1026-1037). [PMID:29471679]
6. Edvinsson L, Haanes KA, Warfvinge K, Krause DN. (2018) CGRP as the target of new migraine therapies - successful translation from bench to clinic.. Nat Rev Neurol, 14 (6): (338-350). [PMID:29691490]
7. A-González N, Castrillo A. (2011) Liver X receptors as regulators of macrophage inflammatory and metabolic pathways.. Biochim Biophys Acta, 1812 (8): (982-94). [PMID:21193033]
8. Edvinsson L. (2018) The CGRP Pathway in Migraine as a Viable Target for Therapies.. Headache, 58 Suppl 1 (3): (33-47). [PMID:29697153]
9. Mallee JJ, Salvatore CA, LeBourdelles B, Oliver KR, Longmore J, Koblan KS, Kane SA. (2002) Receptor activity-modifying protein 1 determines the species selectivity of non-peptide CGRP receptor antagonists.. J Biol Chem, 277 (16): (14294-8). [PMID:11847213]
10. McLatchie LM, Fraser NJ, Main MJ, Wise A, Brown J, Thompson N, Solari R, Lee MG, Foord SM. (1998) RAMPs regulate the transport and ligand specificity of the calcitonin-receptor-like receptor.. Nature, 393 (6683): (333-9). [PMID:9620797]
11. Aiyar N, Disa J, Pullen M, Nambi P. (2001) Receptor activity modifying proteins interaction with human and porcine calcitonin receptor-like receptor (CRLR) in HEK-293 cells.. Mol Cell Biochem, 224 (1-2): (123-33). [PMID:11693189]
12. Doods H, Hallermayer G, Wu D, Entzeroth M, Rudolf K, Engel W, Eberlein W. (2000) Pharmacological profile of BIBN4096BS, the first selective small molecule CGRP antagonist.. Br J Pharmacol, 129 (3): (420-3). [PMID:10711339]
13. Salvatore CA, Hershey JC, Corcoran HA, Fay JF, Johnston VK, Moore EL, Mosser SD, Burgey CS, Paone DV, Shaw AW et al.. (2008) Pharmacological characterization of MK-0974 [N-[(3R,6S)-6-(2,3-difluorophenyl)-2-oxo-1-(2,2,2-trifluoroethyl)azepan-3-yl]-4-(2-oxo-2,3-dihydro-1H-imidazo[4,5-b]pyridin-1-yl)piperidine-1-carboxamide], a potent and orally active calcitonin gene-related peptide receptor antagonist for the treatment of migraine.. J Pharmacol Exp Ther, 324 (2): (416-21). [PMID:18039958]
14. Hay DL, Christopoulos G, Christopoulos A, Sexton PM. (2006) Determinants of 1-piperidinecarboxamide, N-[2-[[5-amino-l-[[4-(4-pyridinyl)-l-piperazinyl]carbonyl]pentyl]amino]-1-[(3,5-dibromo-4-hydroxyphenyl)methyl]-2-oxoethyl]-4-(1,4-dihydro-2-oxo-3(2H)-quinazolinyl) (BIBN4096BS) affinity for calcitonin gene-related peptide and amylin receptors--the role of receptor activity modifying protein 1.. Mol Pharmacol, 70 (3): (1984-1991). [PMID:16959943]
15. Aiyar N, Rand K, Elshourbagy NA, Zeng Z, Adamou JE, Bergsma DJ, Li Y. (1996) A cDNA encoding the calcitonin gene-related peptide type 1 receptor.. J Biol Chem, 271 (19): (11325-9). [PMID:8626685]
16. ter Haar E, Koth CM, Abdul-Manan N, Swenson L, Coll JT, Lippke JA, Lepre CA, Garcia-Guzman M, Moore JM. (2010) Crystal structure of the ectodomain complex of the CGRP receptor, a class-B GPCR, reveals the site of drug antagonism.. Structure, 18 (9): (1083-93). [PMID:20826335]
17. Hong Y, Hay DL, Quirion R, Poyner DR. (2012) The pharmacology of adrenomedullin 2/intermedin.. Br J Pharmacol, 166 (1): (110-20). [PMID:21658025]
18. Liu H, Altenbach RJ, Carr TL, Chandran P, Hsieh GC, Lewis LG, Manelli AM, Milicic I, Marsh KC, Miller TR et al.. (2008) cis-4-(Piperazin-1-yl)-5,6,7a,8,9,10,11,11a-octahydrobenzofuro[2,3-h]quinazolin-2-amine (A-987306), a new histamine H4R antagonist that blocks pain responses against carrageenan-induced hyperalgesia.. J Med Chem, 51 (22): (7094-8). [PMID:18983139]
19. Kusano S, Kukimoto-Niino M, Hino N, Ohsawa N, Okuda K, Sakamoto K, Shirouzu M, Shindo T, Yokoyama S. (2012) Structural basis for extracellular interactions between calcitonin receptor-like receptor and receptor activity-modifying protein 2 for adrenomedullin-specific binding.. Protein Sci, 21 (2): (199-210). [PMID:22102369]
20. Joshi P, Anderson C, Binch H, Hadida S, Yoo S, Bergeron D, Decker C, terHaar E, Moore J, Garcia-Guzman M et al.. (2014) Identification of potent CNS-penetrant thiazolidinones as novel CGRP receptor antagonists.. Bioorg Med Chem Lett, 24 (3): (845-9). [PMID:24405707]
21. Hay DL, Garelja ML, Poyner DR, Walker CS. (2018) Update on the pharmacology of calcitonin/CGRP family of peptides: IUPHAR Review 25.. Br J Pharmacol, 175 (1): (3-17). [PMID:29059473]
22. Luo G, Chen L, Conway CM, Denton R, Keavy D, Signor L, Kostich W, Lentz KA, Santone KS, Schartman R et al.. (2012) Discovery of (5S,6S,9R)-5-amino-6-(2,3-difluorophenyl)-6,7,8,9-tetrahydro-5H-cyclohepta[b]pyridin-9-yl 4-(2-oxo-2,3-dihydro-1H-imidazo[4,5-b]pyridin-1-yl)piperidine-1-carboxylate (BMS-927711): an oral calcitonin gene-related peptide (CGRP) antagonist in clinical trials for treating migraine.. J Med Chem, 55 (23): (10644-51). [PMID:23153230]
23. Bucknell SJ, Ator MA, Brown AJH, Brown J, Cansfield AD, Cansfield JE, Christopher JA, Congreve M, Cseke G, Deflorian F et al.. (2020) Structure-Based Drug Discovery of N-((R)-3-(7-Methyl-1H-indazol-5-yl)-1-oxo-1-(((S)-1-oxo-3-(piperidin-4-yl)-1-(4-(pyridin-4-yl)piperazin-1-yl)propan-2-yl)amino)propan-2-yl)-2'-oxo-1',2'-dihydrospiro[piperidine-4,4'-pyrido[2,3-d][1,3]oxazine]-1-carboxamide (HTL22562): A Calcitonin Gene-Related Peptide Receptor Antagonist for Acute Treatment of Migraine.. J Med Chem, 63 (14): (7906-7920). [PMID:32558564]
24. Mercer SE, Chaturvedula PV, Conway CM, Cook DA, Davis CD, Pin SS, Macci R, Schartman R, Signor LJ, Widmann KA et al.. (2021) Azepino-indazoles as calcitonin gene-related peptide (CGRP) receptor antagonists.. Bioorg Med Chem Lett, 31 (3): (127624). [PMID:33096162]
25. Chaturvedula PV, Mercer SE, Pin SS, Thalody G, Xu C, Conway CM, Keavy D, Signor L, Cantor GH, Mathias N et al.. (2013) Discovery of (R)-N-(3-(7-methyl-1H-indazol-5-yl)-1-(4-(1-methylpiperidin-4-yl)-1-oxopropan-2-yl)-4-(2-oxo-1,2-dihydroquinolin-3-yl)piperidine-1-carboxamide (BMS-742413): a potent human CGRP antagonist with superior safety profile for the treatment of migraine through intranasal delivery.. Bioorg Med Chem Lett, 23 (11): (3157-61). [PMID:23632269]
26. Pan KS, Siow A, Hay DL, Walker CS. (2020) Antagonism of CGRP Signaling by Rimegepant at Two Receptors.. Front Pharmacol, 11 (3): (1240). [PMID:32973499]
27. Guanglin Luo, Ling Chen, Charles M Conway, Rex Denton, Deborah Keavy, Michael Gulianello, Yanling Huang, Walter Kostich, Kimberley A Lentz, Stephen E Mercer, Richard Schartman, Laura Signor, Marc Browning, John E Macor, Gene M Dubowchik,. (2012-04-12) Discovery of BMS-846372, a Potent and Orally Active Human CGRP Receptor Antagonist for the Treatment of Migraine.. ACS medicinal chemistry letters, 3 ((4)): ( 337-341 ). [PMID:24900474]
28. Rudolf K, Eberlein W, Engel W, Pieper H, Entzeroth M, Hallermayer G, Doods H.. (2005) Development of human calcitonin gene-related peptide (CGRP) receptor antagonists. 1. Potent and selective small molecule CGRP antagonists. 1-[N2-[3,5-dibromo-N-[[4-(3,4-dihydro-2(1H)-oxoquinazolin-3-yl)-1-piperidinyl]carbonyl]-D-tyrosyl]-l-lysyl]-4-(4-pyridinyl)piperazine: the first CGRP antagonist for clinical trials in acute migraine.. J Med Chem, 48 (19): (5921-5931). [PMID:16161996]
29. Burgey CS, Stump CA, Nguyen DN, Deng JZ, Quigley AG, Norton BR, Bell IM, Mosser SD, Salvatore CA, Rutledge RZ, Kane SA, Koblan KS, Vacca JP, Graham SL, Williams TM.. (2006) Benzodiazepine calcitonin gene-related peptide (CGRP) receptor antagonists: optimization of the 4-substituted piperidine.. Bioorg Med Chem Lett, 16 (19): (5052-5056). [PMID:16889959]
30. Boeglin D, Hamdan FF, Melendez RE, Cluzeau J, Laperriere A, Héroux M, Bouvier M, Lubell WD.. (2007) Calcitonin gene-related peptide analogues with aza and indolizidinone amino acid residues reveal conformational requirements for antagonist activity at the human calcitonin gene-related peptide 1 receptor.. J Med Chem, 50 (6): (1401-1408). [PMID:17319653]
31. Shaw AW, Paone DV, Nguyen DN, Stump CA, Burgey CS, Mosser SD, Salvatore CA, Rutledge RZ, Kane SA, Koblan KS, Graham SL, Vacca JP, Williams TM.. (2007) Caprolactams as potent CGRP receptor antagonists for the treatment of migraine.. Bioorg Med Chem Lett, 17 (17): (4795-4798). [PMID:17616394]
32. Paone DV, Shaw AW, Nguyen DN, Burgey CS, Deng JZ, Kane SA, Koblan KS, Salvatore CA, Mosser SD, Johnston VK, Wong BK, Miller-Stein CM, Hershey JC, Graham SL, Vacca JP, Williams TM.. (2007) Potent, orally bioavailable calcitonin gene-related peptide receptor antagonists for the treatment of migraine: discovery of N-[(3R,6S)-6-(2,3-difluorophenyl)-2-oxo-1- (2,2,2-trifluoroethyl)azepan-3-yl]-4- (2-oxo-2,3-dihydro-1H-imidazo[4,5-b]pyridin- 1-yl)piperidine-1-carboxamide (MK-0974).. J Med Chem, 50 (23): (5564-5567). [PMID:17929795]
33. Nguyen DN, Paone DV, Shaw AW, Burgey CS, Mosser SD, Johnston V, Salvatore CA, Leonard YM, Miller-Stein CM, Kane SA, Koblan KS, Vacca JP, Graham SL, Williams TM.. (2008) Calcitonin gene-related peptide (CGRP) receptor antagonists: investigations of a pyridinone template.. Bioorg Med Chem Lett, 18 (2): (755-758). [PMID:18039571]
34. Degnan AP, Chaturvedula PV, Conway CM, Cook DA, Davis CD, Denton R, Han X, Macci R, Mathias NR, Moench P, Pin SS, Ren SX, Schartman R, Signor LJ, Thalody G, Widmann KA, Xu C, Macor JE, Dubowchik GM.. (2008) Discovery of (R)-4-(8-fluoro-2-oxo-1,2-dihydroquinazolin-3(4H)-yl)-N-(3-(7-methyl-1H-indazol-5-yl)-1-oxo-1-(4-(piperidin-1-yl)piperidin-1-yl)propan-2-yl)piperidine-1-carboxamide (BMS-694153): a potent antagonist of the human calcitonin gene-related peptide receptor for migraine with rapid and efficient intranasal exposure.. J Med Chem, 51 (16): (4858-4861). [PMID:18665579]
35. Miranda LP, Holder JR, Shi L, Bennett B, Aral J, Gegg CV, Wright M, Walker K, Doellgast G, Rogers R, Li H, Valladares V, Salyers K, Johnson E, Wild K.. (2008) Identification of potent, selective, and metabolically stable peptide antagonists to the calcitonin gene-related peptide (CGRP) receptor.. J Med Chem, 51 (24): (7889-7897). [PMID:19053766]
36. Degnan AP, Conway CM, Dalterio RA, Macci R, Mercer SE, Schartman R, Xu C, Dubowchik GM, Macor JE.. (2009) Carbamates as potent calcitonin gene-related peptide antagonists with improved solution stability.. Bioorg Med Chem Lett, 19 (13): (3555-3558). [PMID:19467597]
37. Nichols PL, Brand J, Briggs M, D'Angeli M, Farge J, Garland SL, Goldsmith P, Hutchings R, Kilford I, Li HY, MacPherson D, Nimmo F, Sanderson FD, Sehmi S, Shuker N, Skidmore J, Stott M, Sweeting J, Tajuddin H, Takle AK, Trani G, Wall ID, Ward R, Wilson DM, Witty D.. (2010) Potent oxadiazole CGRP receptor antagonists for the potential treatment of migraine.. Bioorg Med Chem Lett, 20 (4): (1368-1372). [PMID:20097071]
38. Paone DV, Nguyen DN, Shaw AW, Burgey CS, Potteiger CM, Deng JZ, Mosser SD, Salvatore CA, Yu S, Roller S, Kane SA, Selnick HG, Vacca JP, Williams TM.. (2011) Orally bioavailable imidazoazepanes as calcitonin gene-related peptide (CGRP) receptor antagonists: discovery of MK-2918.. Bioorg Med Chem Lett, 21 (9): (2683-2686). [PMID:21251825]
39. Luo G, Chen L, Civiello R, Pin SS, Xu C, Kostich W, Kelley M, Conway CM, Macor JE, Dubowchik GM.. (2012) Calcitonin gene-related peptide (CGRP) receptor antagonists: pyridine as a replacement for a core amide group.. Bioorg Med Chem Lett, 22 (8): (2917-2921). [PMID:22429470]
40. Han X, Civiello RL, Conway CM, Cook DA, Davis CD, Macci R, Pin SS, Ren SX, Schartman R, Signor LJ, Thalody G, Widmann KA, Xu C, Chaturvedula PV, Macor JE, Dubowchik GM.. (2012) The synthesis and SAR of calcitonin gene-related peptide (CGRP) receptor antagonists derived from tyrosine surrogates. Part 1.. Bioorg Med Chem Lett, 22 (14): (4723-4727). [PMID:22727645]
41. Annedi SC, Maddaford SP, Ramnauth J, Renton P, Rybak T, Silverman S, Rakhit S, Mladenova G, Dove P, Andrews JS, Zhang D, Porreca F.. (2012) Discovery of a potent, orally bioavailable and highly selective human neuronal nitric oxide synthase (nNOS) inhibitor, N-(1-(piperidin-4-yl)indolin-5-yl)thiophene-2-carboximidamide as a pre-clinical development candidate for the treatment of migraine.. Eur J Med Chem, 55 (94-107). [PMID:22840695]
42. Bell IM.. (2014) Calcitonin gene-related peptide receptor antagonists: new therapeutic agents for migraine.. J Med Chem, 57 (19): (7838-7858). [PMID:24960305]
43. Lopez-Tapia F, Walker KA, Brotherton-Pleiss C, Caroon J, Nitzan D, Lowrie L, Gleason S, Zhao SH, Berger J, Cockayne D, Phippard D, Suttmann R, Fitch WL, Bourdet D, Rege P, Huang X, Broadbent S, Dvorak C, Zhu J, Wagner P, Padilla F, Loe B, Jahangir A, Alker A.. (2015) Novel Series of Dihydropyridinone P2X7 Receptor Antagonists.. J Med Chem, 58 (21): (8413-8426). [PMID:26460788]
44. Dubowchik GM, Conway CM, Xin AW.. (2020) Blocking the CGRP Pathway for Acute and Preventive Treatment of Migraine: The Evolution of Success.. J Med Chem, 63 (13): (6600-6623). [PMID:32058712]
45. Flühmann, B B, Muff, R R, Hunziker, W W, Fischer, J A JA and Born, W W.. (1995) A human orphan calcitonin receptor-like structure.. Biochemical and biophysical research communications, (5): [PMID:7818539]
46. Chan, K Y KY and 11 more authors.. (2010) Characterization of the calcitonin gene-related peptide receptor antagonist telcagepant (MK-0974) in human isolated coronary arteries.. The Journal of pharmacology and experimental therapeutics, (1): [PMID:20573757]
47. Walker, Christopher S CS, Raddant, Ann C AC, Woolley, Michael J MJ, Russo, Andrew F AF and Hay, Debbie L DL.. (2018) CGRP receptor antagonist activity of olcegepant depends on the signalling pathway measured.. Cephalalgia : an international journal of headache, [PMID:28165287]
48. Mackie, Duncan I DI and 11 more authors.. (2018) hCALCRL mutation causes autosomal recessive nonimmune hydrops fetalis with lymphatic dysplasia.. The Journal of experimental medicine, (3): [PMID:30115739]
49. Negro, Andrea A and Martelletti, Paolo P.. (2019) Gepants for the treatment of migraine.. Expert opinion on investigational drugs, [PMID:31081399]

Solution Calculators

Molarity Calculator

Determine the necessary mass, volume, or concentration for preparing a solution.

Dilution Calculator

Determine the dilution needed to prepare a stock solution.